Skip to main content
. 2021 Mar 25;10(3):29. doi: 10.1167/tvst.10.3.29

Figure 3.

Figure 3.

Mean fluid reduction from baseline during matched phase. (A) Mean intraretinal fluid (IRF) reduction in treatment agnostic (gray), brolucizumab (blue), and aflibercept (red) groups. (B) Mean subretinal fluid (SRF) reduction in treatment agnostic (gray), brolucizumab (blue), and aflibercept (red) groups. *P < 0.05 brolucizumab versus aflibercept.